Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Aprepitant × Myeloid × Clear all

Phase

Phase NA 2 Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4 Plasma cell 2 Other hematologic neoplasm 2 Gastrointestinal 2 Thoracic 1 Myeloid 1 Gynecologic 1

Conditions

Myeloproliferative Disorders 1

Interventions

Imatinib Mesylate 26 nilotinib 18 Cytarabine 18 Methotrexate 13 Cyclophosphamide 13 Busulfan 13 Hydroxyurea 12 Etoposide 10 Peripheral Blood Stem Cell Transplantation 9 ruxolitinib 8 fludarabine 8 Whole-Body Irradiation 8 fludarabine phosphate 7 Interferon-alpha 7 Idarubicin 7 Tacrolimus 6 Radiotherapy 6 Mitoxantrone 6 Daunorubicin 6 bosutinib 5 asciminib 5 Mycophenolic Acid 5 Melphalan 5 Azacitidine 5 luspatercept 4 Dasatinib 4 Cyclosporine 4 thymoglobulin 3 pegaspargase 3 anagrelide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03808805 2025-12-03

APHYPAP

University Hospital, Brest

Phase 3 Completed

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡